ArticleNature cancer2023

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

Renáta Váraljai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.